Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy.
Bolli
Niccolò
N
Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, University of Perugia, Italy.
Di Ianni
Mauro
M
Simonetti
Stefano
S
Cerroni
Lorenzo
L
Liso
Arcangelo
A
Falini
Brunangelo
B
Tabilio
Antonio
A
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009182:Mycosis Fungoides / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab